{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:23:51Z","timestamp":1785151431867,"version":"3.55.0"},"reference-count":44,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Ovarian cancer (OC) is a significant cause of cancer-related mortality in women globally, with a five-year survival rate of approximately 49%. Standard therapy involves cytoreductive surgery followed by chemotherapy. Its poor prognosis has driven interest in alternative therapies such as targeted molecular agents like bevacizumab and poly (ADP-ribose) polymerase inhibitors (PARPi). Materials and Methods: This review systematically searched PubMed from January 2018 to December 2023 for studies on PARPi in OC. Emphasis was on identifying relevant Phase III trials, extracting data on study design, patient demographics, and outcomes. Special focus was on assessing PARPi efficacy, safety, impact on quality of life, and ongoing trials, including those on Clinicaltrials.gov. Results: The efficacy of PARPi in first-line therapy for OC has been extensively studied. Trials like SOLO-1, PRIMA, and ATHENA-MONO have demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS), particularly in patients with BRCA mutations. Additionally, the combination of PARPi with other agents like bevacizumab has shown promising results in extending PFS. However, PARPi treatment is associated with various adverse effects, including hematologic toxicities like anemia, thrombocytopenia, and neutropenia. While most adverse events are manageable, some patients may require dose adjustments or discontinuation of treatment. Importantly, PARPi maintenance therapy has not adversely affected health-related quality of life (HRQoL), with studies reporting similar HRQoL scores between PARPi-treated and placebo-treated patients. Conclusions: PARPi offer effective treatment with manageable side effects, suitable even for medically fragile patients. Individualized dosing can optimize benefits while minimizing adverse events. Exploring diverse treatment approaches, particularly in patients with limited life expectancy or high disease burden, could improve outcomes. Ongoing research is investigating alternative therapies and combinations to broaden treatment options. Combining bevacizumab with PARPi may be justified for first-line and recurrent maintenance therapy. Regardless of mutational status, PARPi should be considered for maintenance therapy in newly diagnosed advanced OC. Platinum sensitivity remains crucial for treatment decisions and predicting survival outcomes.<\/jats:p>","DOI":"10.3390\/ph17060778","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T08:52:10Z","timestamp":1718355130000},"page":"778","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Tailored Treatment Strategies in First Line Therapy for Ovarian Cancer Patients: A Critical Review of the Literature"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3537-7014","authenticated-orcid":false,"given":"Daniela","family":"Luvero","sequence":"first","affiliation":[{"name":"Department of Gynecology, Fondazione Policlinico Universitario Campus Bio Medico, Via Alvaro del Portillo 200, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Fondazione Policlinico Universitario Campus Bio Medico, Via Alvaro del Portillo 200, 00128 Roma, Italy"},{"name":"Research Unit of Gynecology, Department of Medicine and Surgery, Universit\u00e0 Campus Bio Medico, Via Alvaro del Portillo 21, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Celoro","sequence":"additional","affiliation":[{"name":"Research Unit of Gynecology, Department of Medicine and Surgery, Universit\u00e0 Campus Bio Medico, Via Alvaro del Portillo 21, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Plotti","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Fondazione Policlinico Universitario Campus Bio Medico, Via Alvaro del Portillo 200, 00128 Roma, Italy"},{"name":"Research Unit of Gynecology, Department of Medicine and Surgery, Universit\u00e0 Campus Bio Medico, Via Alvaro del Portillo 21, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Terranova","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Fondazione Policlinico Universitario Campus Bio Medico, Via Alvaro del Portillo 200, 00128 Roma, Italy"},{"name":"Research Unit of Gynecology, Department of Medicine and Surgery, Universit\u00e0 Campus Bio Medico, Via Alvaro del Portillo 21, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Guzzo","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Fondazione Policlinico Universitario Campus Bio Medico, Via Alvaro del Portillo 200, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna Barbara","family":"Cundari","sequence":"additional","affiliation":[{"name":"Research Unit of Gynecology, Department of Medicine and Surgery, Universit\u00e0 Campus Bio Medico, Via Alvaro del Portillo 21, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Liparulo","sequence":"additional","affiliation":[{"name":"Research Unit of Gynecology, Department of Medicine and Surgery, Universit\u00e0 Campus Bio Medico, Via Alvaro del Portillo 21, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Verdone","sequence":"additional","affiliation":[{"name":"Research Unit of Gynecology, Department of Medicine and Surgery, Universit\u00e0 Campus Bio Medico, Via Alvaro del Portillo 21, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Montera","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Fondazione Policlinico Universitario Campus Bio Medico, Via Alvaro del Portillo 200, 00128 Roma, Italy"},{"name":"Research Unit of Gynecology, Department of Medicine and Surgery, Universit\u00e0 Campus Bio Medico, Via Alvaro del Portillo 21, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"ref_1","unstructured":"Kurman, R.J., Carcangiu, M.L., and Harrington, C.S. (2014). WHO Classification of Tumours of Female Reproductive Organs, IARC Publications. [4th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.AOG.0000231680.58221.a7","article-title":"Patterns and Progress in Ovarian Cancer Over 14 Years","volume":"108","author":"Chan","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"x111","DOI":"10.1093\/annonc\/mds300","article-title":"New insights into ovarian cancer pathology","volume":"23","author":"Prat","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3322\/caac.20113","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA A Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5114\/pm.2023.128661","article-title":"Epidemiology and risk factors for ovarian cancer","volume":"22","author":"Ali","year":"2023","journal-title":"Menopausal Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage","volume":"111","author":"Peres","year":"2019","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/1055-9965.EPI-17-0290","article-title":"Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race\/Ethnicity and Histologic Subtypes","volume":"26","author":"Park","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_9","unstructured":"Howlader, N., Noone, A.M., Krapcho, M., Miller, D., Bishop, K., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., and Mariotto, A. (2022, July 06). SEER Cancer Statistics Review, 1975\u20132014, National Cancer Institute. Bethesda, MD, Based on November 2016 SEER Data Submission, Posted to the SEER Web Site, April 2017, Available online: https:\/\/seer.cancer.gov\/csr\/1975_2014\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J","article-title":"A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study","volume":"57","author":"Omura","year":"1986","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/JCO.1989.7.4.457","article-title":"Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group Study","volume":"7","author":"Omura","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III Trial of Carboplatin and Paclitaxel Compared with Cisplatin and Paclitaxel in Patients with Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/OGX.0000000000000613","article-title":"Current First-line Therapy for Ovarian Cancer: A Comprehensive Review","volume":"73","author":"Pierce","year":"2018","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/TCRM.S4317","article-title":"Treatment of recurrent epithelial ovarian cancer","volume":"5","author":"Pignata","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A Phase 3 Trial of Bevacizumab in Ovarian Cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab in Patients with Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel&ndash;carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial","volume":"32","author":"Hilpert","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-1027-1","article-title":"Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment","volume":"14","author":"Papa","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1\/GOG 3004 Trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1073\/pnas.0904783107","article-title":"Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130","volume":"107","author":"Hegan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00280-019-03917-z","article-title":"A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1\/ENGOT-OV24","volume":"84","author":"Mirza","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11523-023-00999-x","article-title":"Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China","volume":"18","author":"Zhao","year":"2023","journal-title":"Target. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with Niraparib Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ygyno.2021.07.016","article-title":"Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial","volume":"163","author":"Colombo","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"112908","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: Results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Pothuri","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/ijgc-2022-004079","article-title":"Safety and management of niraparib monotherapy in ovarian cancer clinical trials","volume":"33","author":"Monk","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ejca.2021.08.023","article-title":"Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1\/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer","volume":"157","author":"Vergote","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S736","DOI":"10.1016\/j.annonc.2021.08.1180","article-title":"Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line maintenance niraparib in patients with advanced ovarian cancer: Results from the PRIMA trial","volume":"32","author":"Monk","year":"2021","journal-title":"Ann Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1470-2045(21)00098-X","article-title":"Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): A randomised, phase 3 trial","volume":"22","author":"Friedlander","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_41","first-page":"A63","article-title":"Patient-reported outcomes in patients receiving niraparib in the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"30","author":"Heitz","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_42","unstructured":"(2024, March 07). Fluzoparib Combined with Bevacizumab in PSROC Previously Treated with PARPi (NCT05551208), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05551208?cond=Ovarian%20Cancer&term=PARP%20Inhibitors&intr=maintenance%20therapy&aggFilters=sex:f&rank=3."},{"key":"ref_43","unstructured":"(2024, March 07). Niraparib and Bevacizumab Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated with a PARP Inhibitor (NIRVANA-R) (NCT04734665), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04734665?cond=Ovarian%20Cancer&term=PARP%20Inhibitors&intr=maintenance%20therapy&aggFilters=sex:f&rank=5."},{"key":"ref_44","unstructured":"(2024, March 07). Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian CancerPatients (ICON9) (NCT03278717), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03278717?cond=Ovarian%20Cancer&term=PARP%20Inhibitors&intr=maintenance%20therapy&aggFilters=sex:f&page=4&rank=32."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/6\/778\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:58:41Z","timestamp":1760108321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/6\/778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ph17060778"],"URL":"https:\/\/doi.org\/10.3390\/ph17060778","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}